Close Menu

NEW YORK (GenomeWeb) – ArcherDx said today that it has entered a research collaboration agreement with the University College London (UCL) and the Francis Crick Institute on lung cancer research.

As part of the agreement, the partners will apply ArcherDx's anchored multiplex PCR (AMP) technology to detect disease recurrence in lung cancer patients from cell-free circulating tumor DNA as part of the UCL-sponsored Tracking Lung Cancer Evolution Through Treatment (TRACERx) study.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.